ANDA 89537, held by Hospira. Procainamide Hydrochloride.
As of Nov 21, 2026, ANDA 89537 (Procainamide Hydrochloride), held by Hospira, was first approved by FDA on Jul 29, 2004, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 29, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Procainamide Hydrochloride500MG/ML · injectable;injection | Procainamide Hydrochloride | Discontinued |
| Jul 29, 2004 | Original application | Approved | None posted |
| Feb 14, 2001 | Supplement 7Manufacturing | Approved | None posted |
| Dec 22, 1995 | Supplement 6Manufacturing | Approved | None posted |
| Jun 26, 1992 | Supplement 4Labeling | Approved | None posted |
| Nov 30, 1990 | Supplement 3Manufacturing | Approved | None posted |
| Jul 6, 1989 | Supplement 2Manufacturing | Approved | None posted |
| Feb 3, 1989 | Supplement 1Labeling | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters